MICONAZOLE NITRATE Canine Year Total Reports Total Probable Total Possible 2015 7 0 7 Presenting signs (probable and possible) Alopecia (localised) (1) Diarrhoea (2) Gagging (1) Deafness (4) Erythema (2) Retching (1) MILBEMYCIN OXIME Milbemycin oxime is a veterinary drug from the group of milbemycins, used as a broad spectrum antiparasitic. It is active against worms (anthelmintic) and mites (miticide). Milbemycin Oxime is present in a number of registered veterinary chemical products in combination with other active constituents and so has a higher number of reports associated with it. The most commonly reported presenting signs included vomiting and lethargy. The number of reports associated with milbemycin oxime is low when compared with the number of doses sold in 2015 (less than 1 in 10 000 doses) and therefore no regulatory action is required other than continued monitoring for unexpected or severe reactions. MILBEMYCIN OXIME Canine Year Total Reports Total Probable Total Possible 2015 193 105 88 Presenting signs (probable and possible) Adipsia (3) Dermatitis (3) Irritation (skin) (1) Agitation (3) Diarrhoea (24) Lack of effect (5) Anorexia (22) Distress (2) Lethargy (48) Ataxia (7) Dysphagia (1) Lump (local) (2) Behavioural change (2) Erythema (3) Malaise (3) Collapse (2) Facial oedema (3) Melaena (1) Convulsions (1) Hypersalivation (3) Nausea (2) Coughing (3) Injection site reaction (2) Neurological disorder (2)
MICONAZOLE NITRATE Canine Year Total Reports Total Probable Total Possible 2015 7 0 7 Presenting signs (probable and possible) Alopecia (localised) (1) Deafness (4) Diarrhoea (2) Erythema (2) Gagging (1) Retching (1) MILBEMYCIN OXIME Milbemycin oxime is a veterinary drug from the group of milbemycins, used as a broad spectrum antiparasitic. It is active against worms (anthelmintic) and mites (miticide). Milbemycin Oxime is present in a number of registered veterinary chemical products in combination with other active constituents and so has a higher number of reports associated with it. The most commonly reported presenting signs included vomiting and lethargy. The number of reports associated with milbemycin oxime is low when compared with the number of doses sold in 2015 (less than 1 in 10 000 doses) and therefore no regulatory action is required other than continued monitoring for unexpected or severe reactions. MILBEMYCIN OXIME Canine Year Total Reports Total Probable Total Possible 2015 193 105 88 Presenting signs (probable and possible) Adipsia (3) Agitation (3) Anorexia (22) Ataxia (7) Behavioural change (2) Collapse (2) Convulsions (1) Coughing (3) Dermatitis (3) Diarrhoea (24) Distress (2) Dysphagia (1) Erythema (3) Facial oedema (3) Hypersalivation (3) Injection site reaction (2) Irritation (skin) (1) Lack of effect (5) Lethargy (48) Lump (local) (2) Malaise (3) Melaena (1) Nausea (2) Neurological disorder (2)
40601-aerp_annual_report_2015_final.docx